Cargando…

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study

OBJECTIVE: To characterize the therapeutic value of new drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the association between these ratings and regulatory approval through expedited programs. DESIGN: Retrospective cohort study. SETTING: New drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Thomas J, Ross, Joseph S, Vokinger, Kerstin N, Kesselheim, Aaron S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537471/ https://www.ncbi.nlm.nih.gov/pubmed/33028575 http://dx.doi.org/10.1136/bmj.m3434

Ejemplares similares

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study
por: Vokinger, Kerstin N, et al.
Publicado: (2023)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

Mitigating bias in machine learning for medicine
por: Vokinger, Kerstin N., et al.
Publicado: (2021)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study
por: Mostaghim, Sana R, et al.
Publicado: (2017)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023)

Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
por: Vokinger, Kerstin Noëlle, et al.
Publicado: (2019)

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
por: Thor, Shannon, et al.
Publicado: (2023)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
por: Shaw, Daniel L., et al.
Publicado: (2018)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2020)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Why Are There So Few FDA-Approved Therapeutics for Wound Healing?
por: Chen, Mei, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
por: Solassol, Isabelle, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hsfb0ofnc5vdqklb27kj0rr81i